GSK
@gsk.bsky.social
We are uniting science, technology and talent to get ahead of disease together.
We’re committed to uncovering the secrets behind disease biology through a new partnership with the Teichmann Lab at the Cambridge Stem Cell Institute called the Human Cell Atlas.
Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW
Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW
December 13, 2025 at 10:00 AM
We’re committed to uncovering the secrets behind disease biology through a new partnership with the Teichmann Lab at the Cambridge Stem Cell Institute called the Human Cell Atlas.
Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW
Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW
#News for #investors and #media: We’re excited to share that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of two potential biologic treatments across three respiratory conditions.
Learn more: gsk.to/48MZ1M2
Learn more: gsk.to/48MZ1M2
December 12, 2025 at 2:08 PM
#News for #investors and #media: We’re excited to share that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of two potential biologic treatments across three respiratory conditions.
Learn more: gsk.to/48MZ1M2
Learn more: gsk.to/48MZ1M2
#News for #investors and #media: The European Medicines Agency’s CHMP have issued a positive opinion on the expansion to a younger population for one of our vaccines.
Access our website here: gsk.to/4aLrWTg
Access our website here: gsk.to/4aLrWTg
December 12, 2025 at 7:08 AM
#News for #investors and #media: The European Medicines Agency’s CHMP have issued a positive opinion on the expansion to a younger population for one of our vaccines.
Access our website here: gsk.to/4aLrWTg
Access our website here: gsk.to/4aLrWTg
#News for #Media and #Investors: Today, we are announcing that one of our oral anti-infectives has been approved by the FDA.
Learn more: www.gsk.com
Learn more: www.gsk.com
December 11, 2025 at 8:59 PM
#News for #Media and #Investors: Today, we are announcing that one of our oral anti-infectives has been approved by the FDA.
Learn more: www.gsk.com
Learn more: www.gsk.com
#News for #Investors and #Media: Today we announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more here: gsk.to/4rFbiuy
Learn more here: gsk.to/4rFbiuy
December 10, 2025 at 7:06 AM
#News for #Investors and #Media: Today we announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more here: gsk.to/4rFbiuy
Learn more here: gsk.to/4rFbiuy
Globally, more than 1 million people are diagnosed with a blood cancer each year.
Through our latest research programmes, we are innovating for patients with blood cancers to help address their unmet needs.
Watch to learn more.
#ASH25
Through our latest research programmes, we are innovating for patients with blood cancers to help address their unmet needs.
Watch to learn more.
#ASH25
December 9, 2025 at 3:00 PM
Globally, more than 1 million people are diagnosed with a blood cancer each year.
Through our latest research programmes, we are innovating for patients with blood cancers to help address their unmet needs.
Watch to learn more.
#ASH25
Through our latest research programmes, we are innovating for patients with blood cancers to help address their unmet needs.
Watch to learn more.
#ASH25
Outsmarting cancer demands focus 🔍
That’s why we’re channelling our science and technology where it can make the biggest difference for people living with cancer.
Catch us at #ASH25 this weekend!
That’s why we’re channelling our science and technology where it can make the biggest difference for people living with cancer.
Catch us at #ASH25 this weekend!
December 8, 2025 at 12:00 PM
Outsmarting cancer demands focus 🔍
That’s why we’re channelling our science and technology where it can make the biggest difference for people living with cancer.
Catch us at #ASH25 this weekend!
That’s why we’re channelling our science and technology where it can make the biggest difference for people living with cancer.
Catch us at #ASH25 this weekend!
Big news for U.S. innovation!
We've officially opened our new Vaccine & Infectious Disease R&D HQ in Boston's Cambridge Park Drive. This expanded space is central to our 5-year investment in the U.S., driving faster, better innovation for patients globally.
We've officially opened our new Vaccine & Infectious Disease R&D HQ in Boston's Cambridge Park Drive. This expanded space is central to our 5-year investment in the U.S., driving faster, better innovation for patients globally.
December 4, 2025 at 6:00 PM
Big news for U.S. innovation!
We've officially opened our new Vaccine & Infectious Disease R&D HQ in Boston's Cambridge Park Drive. This expanded space is central to our 5-year investment in the U.S., driving faster, better innovation for patients globally.
We've officially opened our new Vaccine & Infectious Disease R&D HQ in Boston's Cambridge Park Drive. This expanded space is central to our 5-year investment in the U.S., driving faster, better innovation for patients globally.
We’re looking forward to being on the ground at #ASH25 this weekend, presenting our latest progress in blood cancer research.
What are you most excited for during this year’s congress? 👇
What are you most excited for during this year’s congress? 👇
December 2, 2025 at 5:00 PM
We’re looking forward to being on the ground at #ASH25 this weekend, presenting our latest progress in blood cancer research.
What are you most excited for during this year’s congress? 👇
What are you most excited for during this year’s congress? 👇
#News for #investors and #media: We are pleased to present new data from our #bloodcancer pipeline and portfolio at #ASH25.
Learn more: gsk.to/4oKX2xX
Learn more: gsk.to/4oKX2xX
December 1, 2025 at 2:54 PM
#News for #investors and #media: We are pleased to present new data from our #bloodcancer pipeline and portfolio at #ASH25.
Learn more: gsk.to/4oKX2xX
Learn more: gsk.to/4oKX2xX
2000 ➡️ 2025: celebrating 25 years of partnership with the @who.int on the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4
🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4
November 28, 2025 at 3:55 PM
2000 ➡️ 2025: celebrating 25 years of partnership with the @who.int on the Global Programme to Eliminate Lymphatic Filariasis (GPELF).
🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4
🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4
“More years in life, and more life in those years."
That's what drives our research for people living with multiple myeloma 🧡
Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research.
🎥 Watch the conversation: bit.ly/4rfYhaC
That's what drives our research for people living with multiple myeloma 🧡
Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research.
🎥 Watch the conversation: bit.ly/4rfYhaC
November 28, 2025 at 1:00 PM
“More years in life, and more life in those years."
That's what drives our research for people living with multiple myeloma 🧡
Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research.
🎥 Watch the conversation: bit.ly/4rfYhaC
That's what drives our research for people living with multiple myeloma 🧡
Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research.
🎥 Watch the conversation: bit.ly/4rfYhaC
For Covid-19 and influenza, the risks are well-known but many people underestimate respiratory syncytial virus, or RSV.
🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL
🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL
November 22, 2025 at 10:00 AM
For Covid-19 and influenza, the risks are well-known but many people underestimate respiratory syncytial virus, or RSV.
🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL
🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL
80 years after the Nobel Prize for penicillin, antimicrobial resistance is one of societies toughest challenges. GSK, the Fleming Initiative, and the @ineosoxford.bsky.social hosted leaders at the Royal Society of Medicine to advance the global response.
November 20, 2025 at 3:28 PM
80 years after the Nobel Prize for penicillin, antimicrobial resistance is one of societies toughest challenges. GSK, the Fleming Initiative, and the @ineosoxford.bsky.social hosted leaders at the Royal Society of Medicine to advance the global response.
Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.
November 19, 2025 at 3:00 PM
Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.
COPD affects over 390 million people globally, significantly impacting patients like Val and their families.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
November 19, 2025 at 10:00 AM
COPD affects over 390 million people globally, significantly impacting patients like Val and their families.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD
November 18, 2025 at 10:59 AM
We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD
Living with blood cancer often means lifelong treatment, frequent hospital visits, and managing challenging side effects.
But what if there are more ways to improve both care and quality of life?
🔗 Read more: bit.ly/43z2Brb
But what if there are more ways to improve both care and quality of life?
🔗 Read more: bit.ly/43z2Brb
November 13, 2025 at 10:00 AM
Living with blood cancer often means lifelong treatment, frequent hospital visits, and managing challenging side effects.
But what if there are more ways to improve both care and quality of life?
🔗 Read more: bit.ly/43z2Brb
But what if there are more ways to improve both care and quality of life?
🔗 Read more: bit.ly/43z2Brb
We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies.
Watch this video to learn more about our approach to unlocking the power of prevention 👇
Watch this video to learn more about our approach to unlocking the power of prevention 👇
November 11, 2025 at 3:08 PM
We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies.
Watch this video to learn more about our approach to unlocking the power of prevention 👇
Watch this video to learn more about our approach to unlocking the power of prevention 👇
#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC.
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
November 7, 2025 at 1:52 PM
#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC.
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
Join us at the American Society of Nephrology congress this week, as we partner with nephrology leaders to talk about the importance of protecting kidney function and supporting long-term health outcomes for people living with lupus.
November 5, 2025 at 3:00 PM
Join us at the American Society of Nephrology congress this week, as we partner with nephrology leaders to talk about the importance of protecting kidney function and supporting long-term health outcomes for people living with lupus.
"One person doesn’t make a difference. We all come together, and we make it happen.”
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
October 30, 2025 at 2:00 PM
"One person doesn’t make a difference. We all come together, and we make it happen.”
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025.
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
October 29, 2025 at 7:21 AM
Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025.
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases.
Find out more: gsk.to/4oF5Vt6
Find out more: gsk.to/4oF5Vt6
October 28, 2025 at 7:15 AM
#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases.
Find out more: gsk.to/4oF5Vt6
Find out more: gsk.to/4oF5Vt6
#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more here: gsk.to/4hwnHfz
Learn more here: gsk.to/4hwnHfz
October 28, 2025 at 7:07 AM
#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more here: gsk.to/4hwnHfz
Learn more here: gsk.to/4hwnHfz